NEULANDLABNSENeuland Laboratories Limited· PharmaceuticalsMediumNeutral
Announced Tue, 7 Apr · 12:58 IST

Neuland Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Ownership Changes View source PDF

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+7.6%1-day move
₹13100.00
prior close
₹13355.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0+0.9+1.2+1.0+7.6+12.4+14.1+10.7+14.8+16.6+11.8+30.9+28.9+44.4
Up moveDown movePending
AI summary

Dr. Davuluri Rama Mohan Rao, a promoter of Neuland Laboratories Limited, has submitted a negative declaration confirming that neither he nor any other member of the Promoter and Promoter Group created any new share encumbrances (pledges) during the financial year 2025-26. This filing is a routine compliance requirement under SEBI regulations requiring promoters to disclose encumbrance activity periodically. The declaration states that no encumbrances were made beyond what was already previously disclosed.

Likely market impact

This is a routine regulatory filing and the absence of new encumbrances is generally viewed as a positive signal by the market, indicating that promoter holdings remain unencumbered and reducing risk of forced share sales that could impact stock price.